388 related articles for article (PubMed ID: 26842585)
1. Emerging drugs affecting skeletal muscle function and mitochondrial biogenesis - Potential implications for sports drug testing programs.
Thevis M; Schänzer W
Rapid Commun Mass Spectrom; 2016 Mar; 30(5):635-51. PubMed ID: 26842585
[TBL] [Abstract][Full Text] [Related]
2. Expanding sports drug testing assays: mass spectrometric characterization of the selective androgen receptor modulator drug candidates RAD140 and ACP-105.
Thevis M; Piper T; Beuck S; Geyer H; Schänzer W
Rapid Commun Mass Spectrom; 2013 Jun; 27(11):1173-82. PubMed ID: 23650030
[TBL] [Abstract][Full Text] [Related]
3. Studies on the collision-induced dissociation of adipoR agonists after electrospray ionization and their implementation in sports drug testing.
Dib J; Schlörer N; Schänzer W; Thevis M
J Mass Spectrom; 2015 Feb; 50(2):407-17. PubMed ID: 25800023
[TBL] [Abstract][Full Text] [Related]
4. Fragmentation studies of SIRT1-activating drugs and their detection in human plasma for doping control purposes.
Höppner S; Schänzer W; Thevis M
Rapid Commun Mass Spectrom; 2013 Jan; 27(1):35-50. PubMed ID: 23239315
[TBL] [Abstract][Full Text] [Related]
5. Sports drug testing using complementary matrices: Advantages and limitations.
Thevis M; Geyer H; Tretzel L; Schänzer W
J Pharm Biomed Anal; 2016 Oct; 130():220-230. PubMed ID: 27040951
[TBL] [Abstract][Full Text] [Related]
6. Confiscated black market products and nutritional supplements with non-approved ingredients analyzed in the Cologne Doping Control Laboratory 2009.
Kohler M; Thomas A; Geyer H; Petrou M; Schänzer W; Thevis M
Drug Test Anal; 2010; 2(11-12):533-7. PubMed ID: 21204286
[TBL] [Abstract][Full Text] [Related]
7. Mass spectrometric characterization of a prolyl hydroxylase inhibitor GSK1278863, its bishydroxylated metabolite, and its implementation into routine doping controls.
Thevis M; Milosovich S; Licea-Perez H; Knecht D; Cavalier T; Schänzer W
Drug Test Anal; 2016 Aug; 8(8):858-63. PubMed ID: 26361079
[TBL] [Abstract][Full Text] [Related]
8. Annual banned-substance review: analytical approaches in human sports drug testing.
Thevis M; Kuuranne T; Geyer H; Schänzer W
Drug Test Anal; 2013 Jan; 5(1):1-19. PubMed ID: 23229872
[TBL] [Abstract][Full Text] [Related]
9. Annual banned-substance review: analytical approaches in human sports drug testing.
Thevis M; Kuuranne T; Geyer H; Schänzer W
Drug Test Anal; 2015 Jan; 7(1):1-20. PubMed ID: 25545248
[TBL] [Abstract][Full Text] [Related]
10. Targeting prohibited substances in doping control blood samples by means of chromatographic-mass spectrometric methods.
Thevis M; Thomas A; Schänzer W
Anal Bioanal Chem; 2013 Dec; 405(30):9655-67. PubMed ID: 23925796
[TBL] [Abstract][Full Text] [Related]
11. Mass spectrometric studies on the in vivo metabolism and excretion of SIRT1 activating drugs in rat urine, dried blood spots, and plasma samples for doping control purposes.
Höppner S; Delahaut P; Schänzer W; Thevis M
J Pharm Biomed Anal; 2014 Jan; 88():649-59. PubMed ID: 24239904
[TBL] [Abstract][Full Text] [Related]
12. Mass spectrometry-based characterization of new drugs and methods of performance manipulation in doping control analysis.
Thevis M; Thomas A; Kohler M; Beuck S; Möller I; Schäfer M; Rodchenkov G; Yin S; Loo JA; Geyer H; Schänzer W
Eur J Mass Spectrom (Chichester); 2010; 16(3):301-12. PubMed ID: 20530837
[TBL] [Abstract][Full Text] [Related]
13. Characterization of two major urinary metabolites of the PPARdelta-agonist GW1516 and implementation of the drug in routine doping controls.
Thevis M; Möller I; Thomas A; Beuck S; Rodchenkov G; Bornatsch W; Geyer H; Schänzer W
Anal Bioanal Chem; 2010 Apr; 396(7):2479-91. PubMed ID: 19946680
[TBL] [Abstract][Full Text] [Related]
14. Annual banned-substance review: analytical approaches in human sports drug testing.
Thevis M; Kuuranne T; Walpurgis K; Geyer H; Schänzer W
Drug Test Anal; 2016 Jan; 8(1):7-29. PubMed ID: 26767774
[TBL] [Abstract][Full Text] [Related]
15. Annual banned-substance review: analytical approaches in human sports drug testing.
Thevis M; Kuuranne T; Geyer H; Schänzer W
Drug Test Anal; 2012 Jan; 4(1):2-16. PubMed ID: 22287289
[TBL] [Abstract][Full Text] [Related]
16. Synthesis, mass spectrometric characterization, and analysis of the PPARδ agonist GW1516 and its major human metabolites: targets in sports drug testing.
Thevis M; Möller I; Beuck S; Schänzer W
Methods Mol Biol; 2013; 952():301-12. PubMed ID: 23100242
[TBL] [Abstract][Full Text] [Related]
17. In vitro metabolism studies on the selective androgen receptor modulator (SARM) LG121071 and its implementation into human doping controls using liquid chromatography-mass spectrometry.
Knoop A; Krug O; Vincenti M; Schänzer W; Thevis M
Eur J Mass Spectrom (Chichester); 2015; 21(1):27-36. PubMed ID: 25906032
[TBL] [Abstract][Full Text] [Related]
18. Annual banned-substance review: analytical approaches in human sports drug testing.
Thevis M; Kuuranne T; Geyer H; Schänzer W
Drug Test Anal; 2011 Jan; 3(1):1-14. PubMed ID: 21254451
[TBL] [Abstract][Full Text] [Related]
19. Doping control analysis of selected peptide hormones using LC-MS(/MS).
Thevis M; Thomas A; Schänzer W
Forensic Sci Int; 2011 Dec; 213(1-3):35-41. PubMed ID: 21752560
[TBL] [Abstract][Full Text] [Related]
20. Trafficking of drug candidates relevant for sports drug testing: detection of non-approved therapeutics categorized as anabolic and gene doping agents in products distributed via the Internet.
Thevis M; Geyer H; Thomas A; Schänzer W
Drug Test Anal; 2011 May; 3(5):331-6. PubMed ID: 21538997
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
